F2G Biotech GmbH

Quick facts

Phase 1 pipeline

• F901318 Dose level A oral
• F901318 Dose level B oral
• F901318 Dose level C oral
• F901318 IR
• F901318 IR Fasting
• F901318 IR Fed
• F901318 pharmacokinetics
• F901318 safety
• F901318 SDD
• F901318 tolerability
• Midazolam with F901318

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• F2G Biotech GmbH portfolio CI brief
• F2G Biotech GmbH pipeline updates RSS